**5. Conclusions**

A higher TST level (≥13 ng/dL) was associated with a favorable prognosis in Enza- and/or Abi-treated patients. A TST level of 13 ng/dL may predict a favorable response to novel AR-targeted drugs in CRPC patients.

*J. Clin. Med.* **2019**, *8*, 489

**Supplementary Materials:** The supplementary materials are available online at http://www.mdpi.com/2077- 0383/8/4/489/s1.

**Author Contributions:** S.S. designed the study, collected the data, and completed the manuscript. M.X. and M.M. performed the statistical analysis. H.A.U. supervised the statistical analysis. S.K., Y.Y., H.K., H.M. (Hiroaki Matsumoto), N.T., K.H., M.N., H.N., H.M. (Hideyasu Matsuyama) collected the data. A.K., K.A., T.I. supervised the manuscript. All authors have read and approved the final version of the manuscript and agree with the order of presentation of the authors.

**Funding:** The present work was supported by a Grant-in-Aid for Scientific Research(C) (grant #25462469) to S. Sakamoto.

**Acknowledgments:** The authors are grateful to all members of Chiba University Hospital and the four related institutions for collecting and analyzing the patients' data. The authors particularly appreciate the help of Hisayo Karahi, a research assistant, for the documentation work.

**Conflicts of Interest:** The authors declare no conflict of interest.
